Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Dompé, Mesoblast, Mustang, Oblato, Pharmacyte.
LONDON – New evidence from seven randomized controlled trials and a simultaneously conducted meta-analysis has again demonstrated that corticosteroids show significant benefit in patients who are critically ill with COVID-19, reducing length of hospital stay and cutting 28-day mortality.
TORONTO – Its Canadian medical device establishment licence now firmly in hand, Toronto-based Internet of Things Inc. (ITT) is set to launch a fever-detection system for identifying possible COVID-19 carriers at the entrances of airports, long term care facilities, schools and other places where people congregate. The Thermalpass is an AI-enabled, deep learning screening system that got its start as a road-related weather sensing system, today detecting elevated body temperature.
The idea of being able to produce vaccines at the point of care with the push of a button may sound futuristic, but Codex DNA Inc. claims it will have the first fully automated, tabletop vaccine printer ready for the market in 18-24 months. Will this be a game-changer in rolling out a COVID-19 vaccine? Probably not. But the technology could better position health officials to respond to the next pandemic, or eventually to produce a better, faster influenza vaccine each year.
NEW DELHI – A COVID-19 diagnostic test kit developed by the Indian Institute of Technology (IIT) in New Delhi is the latest to join a growing pool of low-cost kits domestically developed in a country where the number of cases topped 2 million in August and continues to rise. The push to develop test kits domestically is part of a national effort to shake off a heavy dependence on imports of medical devices, including diagnostic kits.
As 2020 approaches its last quarter, scientists around the globe continue their all-consuming efforts to find effective therapeutics and vaccines to fight the deadly COVID-19 pandemic, which currently has a 3.35% fatality rate and has been plaguing the world for more than half a year. While the fight rages on, people are growing weary of political posturing and community debates. They face a serious conundrum of how to best protect those vulnerable to the virus, while still considering the psychological and economic impacts of societal lockdowns.
With a potential COVID-19 vaccine moving closer to reality and the U.S government signing contracts for millions of potential doses, an unresolved question is who should be at the front of the line to get those first doses.
DUBLIN – Sanofi SA and Regeneron Pharmaceuticals Inc. are terminating all further development in COVID-19 of their interleukin-6 receptor inhibitor, Kevzara, following the antibody’s failure to meet the primary endpoint, as well as a key survival endpoint.
RSS
